849217-68-1 | N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$15.00	$10.00
100mg	98%	in stock	$32.00	$22.00
250mg	98%	in stock	$49.00	$34.00
1g	98%	in stock	$113.00	$79.00
5g	98%	in stock	$341.00	$239.00
10g	98%	in stock	$605.00	$423.00
25g	98%	in stock	$1,195.00	$836.00

Description

• Catalog Number: AB53042
• Chemical Name: N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
• CAS Number: 849217-68-1
• Molecular Formula: C28H24FN3O5
• Molecular Weight: 501.5057
• MDL Number: MFCD20926324
• SMILES: COc1cc2c(ccnc2cc1OC)Oc1ccc(cc1)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F

Computed Properties

• Complexity: 795
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 8
• XLogP3: 5.4

Literature

• Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

  Toxicology letters 20180701

• Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

  Cancer discovery 20180701

• Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.

  Expert review of clinical pharmacology 20160101

• Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

  The New England journal of medicine 20151105

• Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20140101

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Novel molecular targeted therapies for refractory thyroid cancer.

  Head & neck 20120501

• Novel molecular targets for the therapy of castration-resistant prostate cancer.

  European urology 20120501

• Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.

  Cancer discovery 20120301

• c-Met is a marker of pancreatic cancer stem cells and therapeutic target.

  Gastroenterology 20111201

• Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

  Molecular cancer therapeutics 20111201

• Novel therapies for metastatic castrate-resistant prostate cancer.

  Journal of the National Cancer Institute 20111116

• Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

  Drugs of today (Barcelona, Spain : 1998) 20111101

• VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.

  Cancer research 20110715

• Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110615

• The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.

  The Journal of clinical endocrinology and metabolism 20110601

• XL184 (cabozantinib) for medullary thyroid carcinoma.

  Expert opinion on investigational drugs 20110301

• Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.

  Endocrine journal 20110101

• Novel treatment of medullary thyroid cancer.

  Current opinion in endocrinology, diabetes, and obesity 20091001